Advertisement

U.S. markets open in 9 hours 5 minutes

S&P Futures
3,839.50
+12.25(+0.32%)
Dow Futures
31,136.00
+75.00(+0.24%)
Nasdaq Futures
11,665.75
+54.50(+0.47%)
Russell 2000 Futures
1,732.00
+3.50(+0.20%)
Crude Oil
110.26
+1.83(+1.69%)
Gold
1,811.70
+10.20(+0.57%)

Advertisement

BuzzFeed, Inc. (BZFD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

1.6200

+0.0800

(+5.19%)

At close: 04:00PM EDT

1.6500

+0.03

(+1.85%)

After hours:

07:35PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Intermediate-term KST

View all chart patterns

Performance Outlook

Previous Close	1.5400
Open	1.5400
Bid	1.5800 x 800
Ask	1.6500 x 1000
Day's Range	1.5300 - 1.6300
52 Week Range	1.5000 - 14.7700
Volume	122,353
Avg. Volume	369,760

Market Cap	219.447M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-0.5990
Earnings Date	May 16, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	5.17

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

-2% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BZFD

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

BuzzFeed, Inc.
Analyst Report: 23andMe Holding Co.23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
Rating
Fair Value
Economic Moat
18 days agoMorningstar